AIDS Weekly
Susan Hasty, Publisher
Table of Contents . . . February 16th, 2004
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in AIDS Weekly | Other Publications
Drug Development - Fungal metabolite inhibits HIV integrase activity
Corporate Update - Biopharmaceutical company transformation completed
Drug Development - Mirror-image Zintevir analogue has similar anti-HIV activity
HIV/AIDS - In Mozambique, stigma remains obstacle to treatment for HIV+ women
HIV/AIDS Diagnostics - Three rapid immunoassays suitable for detection of non-B HIV subtypes
HIV/AIDS Drug Monitoring - LC/MS/MS assay enables ddI, d4T monitoring in wide range of specimen types
HIV/AIDS Drug Resistance - Role of secondary mutations in protease inhibitor resistance evaluated
HIV/AIDS Immunology - Virus-specific CD154 induction impaired in CD4 cells
HIV/AIDS Lipodystrophy - Heightened cytokine activity involved in pathogenesis
HIV/AIDS Lipodystrophy - Metabolic growth hormone regulation characterized
HIV/AIDS Neurodegeneration - Mechanisms of HIV-related encephalopathy in children elucidated
HIV/AIDS Therapy - Amprenavir prodrug safe and effective, with reduced pill burden
HIV/AIDS Neurodegeneration - Meth addiction increases risk of neuropsychological damage in HIV patients
HIV/AIDS Neurodegeneration - Perceptual span impairment in HIV patients characterized
HIV/AIDS Opportunistic Infection - Mycobacterium kansasii-induced septal perforation reported
HIV/AIDS Opportunistic Infection - Mechanisms of Hst 5 candidacidal activity clarified
HIV/AIDS Opportunistic Infection - Risk of drug-resistant P. aeruginosa reduced in HAART era
HIV/AIDS Pathogenesis - Fucosylated lactosamines help mediate HIV adhesion to dendritic cells
HIV/AIDS Pathogenesis - HIV Nef-mediated MHC-I downmodulation is independent of Arf6 activity
HIV/AIDS Therapy - Enzyme immunoassay enables intracellular nevirapine measurment
HIV/AIDS Therapy - European, U.S. HIV prescribers rank top treatment goals
HIV/AIDS Therapy - Tenofovir DF pharmacokinetics similar in children and adults
Drug Development - Novel CCR5 antagonists show promise and anti-HIV agents
HIV/AIDS Treatment - Lexiva well tolerated in phase III, 48-week study versus nelfinavir
HIV/AIDS Treatment - Viracept 625 mg receives positive opinion in Europe
HIV/AIDS Vaccine - Broadly cross-reactive HIV-neutralizing antibody Fab identified
Hemophilia - Treatment for HIV and HCV infections in hemophiliacs reviewed
Personnel - Biopharmaceutical company announces changes to management and board
Personnel - Michael Markels to lead sales and marketing for neuropathic pain company
Protein Therapy - Fusion of HIV Tat PTD at both termini improves protein uptake
Substance Abuse - Black tar heroin use explains lower HIV levels among injection drug users
Drug Development - Novel NNRTIs prevent HIV infection in vitro
HIV/AIDS RNA Research - Pseudoknots are key feature of RNA aptamers that bind HIV NC protein
HIV/AIDS Therapy - Once-daily lamivudine 300 mg equivalent to 150 mg BID
AIDS - Cheaper drugs force life-and-decisions for poor AIDS patients
AIDS Therapy - Action needed to avoid HIV drug resistance in Africa
AIDS Therapy - Patient enrollment completed in HIV vaccine trial
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
